Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Paclitaxel in Advanced Esophageal SCC
NCT03762564Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Mar 2019
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ramucirumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall Survival at 6 months. Started Mar 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03762564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762564.